Form 4: NeueHealth Director Acquires Warrants Following NYSE Notification

Anthony A. Florence, Jr., a director at NeueHealth, reported the acquisition of warrants exercisable for common stock, following the company's notification to the NYSE.

Summary

• Anthony A. Florence, Jr., a director of NeueHealth, filed a Form 4 disclosing the acquisition of warrants.
• The warrants, acquired on April 8, 2024, are exercisable for NeueHealth common stock.
• The warrants were issued pursuant to a Warrantholders Agreement dated April 8, 2024, and a Credit Agreement dated August 4, 2023, as amended.
• The warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual.
• The warrants are exercisable any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date.
• The reporting person disclaims beneficial ownership of the securities held by NEA 15, NEA 16, NEA 17 and NEA 18 VGE in which the Reporting Person has no pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing related to insider transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Positives

• The acquisition of warrants by a director could be seen as a sign of confidence in the company's future prospects.

Future Outlook

The warrants are exercisable at any time after issuance and prior to the close of business on the fifth anniversary of the Closing Date.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's acquisition of warrants, which is a common form of equity compensation.

Comparison to Industry Standards

• Equity compensation in the form of warrants is a common practice among publicly traded companies, particularly in the healthcare sector, to align the interests of directors and management with those of shareholders.
• The terms of the warrants, such as the exercise price and expiration date, are generally consistent with industry standards for equity compensation.

Stakeholder Impact

• The acquisition of warrants by a director could potentially impact shareholders by increasing the number of shares outstanding upon exercise, which could dilute existing shareholders' ownership.

Next Steps

• The warrants will be issued on the first business day following the conclusion of the 10 calendar day period after the distribution of the letter required to be mailed by the Issuer to its shareholders pursuant to Section 312.05 of the NYSE Listed Company Manual.

Key Dates